Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy-Reference-Cited by-同舟云学术

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

Published:2021-02 Issue: Volume:Volume 13 Page:121-133
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Ghetti Gianni,D'Avella Maria Claudia,Pradelli Lorenzo^ORCID

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference48 articles.

1. AIOM. Tumori cutanei non melanoma. Carcinoma squamocellulare cutaneo. Edizione; 2019. Available from: https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_CSquamocellulare.pdf. Accessed January 26, 2021

2. AIRTUM. Analisi epidemiologica e caratterizzazione morfologica di pazienti affetti da tumore della cute non melanoma da registro nazionale AIRTUM. Available from: https://www.registri-tumori.it/cms/pubblicazioni/report-i-tumori-cutanei. Accessed January 26, 2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system;BMC Health Services Research;2023-06-08

2. Cemiplimab in advanced cutaneous squamous cell carcinoma;Dermatologic Therapy;2021-11

3. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma;Expert Opinion on Drug Safety;2021-11-01

4. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%;Advances in Therapy;2021-07-09

5. Is cemiplimab cost effective in advanced cutaneous squamous cell carcinoma?;PharmacoEconomics & Outcomes News;2021-02